Immunome To Present Poster Highlighting Preclinical Evaluation Of IM-1021, A ROR1-Targeted Antibody Drug Conjugate, At The 36th EORTC-NCI-AACR Symposium

Benzinga · 10/18 12:02

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024.